VRTX · 10-Q · 2026Q2 · Full report
Litigation and Legal Risk
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 47 · Surprise 60 · In source text
On October 10, 2025, Royalty Pharma initiated confidential arbitration concerning the royalty burden payable on ALYFTREK under Vertex’s agreement with the Cystic Fibrosis Foundation. Royalty Pharma alleges that the ALYFTREK royalty rate is approximately 8%, compared with Vertex’s position that the rate is 4%. The claimant seeks a declaratory judgment, alleged unpaid royalties and other damages, plus costs, attorneys’ fees and interest. Vertex disputes the claim and plans to defend its contractual position.
Key facts
- Oct 10, 2025: Royalty Pharma initiated a confidential arbitration alleging ALYFTREK royalty burden is approximately 8% and seeking declaratory judgment and alleged unpaid royalties and damages source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | — | Oct 10, 2025: Royalty Pharma initiated a confidential arbitration alleging ALYFTREK royalty burden is approximately 8% and seeking… |